vs

Side-by-side financial comparison of DoubleVerify Holdings, Inc. (DV) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $205.6M, roughly 1.0× DoubleVerify Holdings, Inc.). DoubleVerify Holdings, Inc. runs the higher net margin — 14.3% vs -62.0%, a 76.3% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 7.9%). DoubleVerify Holdings, Inc. produced more free cash flow last quarter ($62.1M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 20.8%).

Double Vision is a Malaysian production studio. Established in 1985, it has production hubs in Malaysia and Indonesia. Double Vision produces over 1,400 hours of television programming per year in various languages and genres for the regional market. It also houses international entertainment TV network, Channel [V], in its studios.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

DV vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.0× larger
RARE
$207.3M
$205.6M
DV
Growing faster (revenue YoY)
RARE
RARE
+18.0% gap
RARE
25.9%
7.9%
DV
Higher net margin
DV
DV
76.3% more per $
DV
14.3%
-62.0%
RARE
More free cash flow
DV
DV
$162.9M more FCF
DV
$62.1M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
20.8%
DV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DV
DV
RARE
RARE
Revenue
$205.6M
$207.3M
Net Profit
$29.3M
$-128.6M
Gross Margin
82.5%
Operating Margin
18.4%
-54.7%
Net Margin
14.3%
-62.0%
Revenue YoY
7.9%
25.9%
Net Profit YoY
25.3%
3.5%
EPS (diluted)
$0.18
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DV
DV
RARE
RARE
Q4 25
$205.6M
$207.3M
Q3 25
$188.6M
$159.9M
Q2 25
$189.0M
$166.5M
Q1 25
$165.1M
$139.3M
Q4 24
$190.6M
$164.6M
Q3 24
$169.6M
$139.5M
Q2 24
$155.9M
$147.0M
Q1 24
$140.8M
$108.8M
Net Profit
DV
DV
RARE
RARE
Q4 25
$29.3M
$-128.6M
Q3 25
$10.2M
$-180.4M
Q2 25
$8.8M
$-115.0M
Q1 25
$2.4M
$-151.1M
Q4 24
$23.4M
$-133.2M
Q3 24
$18.2M
$-133.5M
Q2 24
$7.5M
$-131.6M
Q1 24
$7.2M
$-170.7M
Gross Margin
DV
DV
RARE
RARE
Q4 25
82.5%
Q3 25
82.3%
Q2 25
82.5%
Q1 25
81.2%
Q4 24
82.0%
Q3 24
82.6%
Q2 24
83.3%
Q1 24
81.1%
Operating Margin
DV
DV
RARE
RARE
Q4 25
18.4%
-54.7%
Q3 25
11.2%
-106.9%
Q2 25
7.2%
-64.8%
Q1 25
4.1%
-102.6%
Q4 24
20.3%
-74.3%
Q3 24
15.2%
-94.6%
Q2 24
7.1%
-79.1%
Q1 24
4.9%
-151.9%
Net Margin
DV
DV
RARE
RARE
Q4 25
14.3%
-62.0%
Q3 25
5.4%
-112.8%
Q2 25
4.6%
-69.0%
Q1 25
1.4%
-108.5%
Q4 24
12.3%
-80.9%
Q3 24
10.7%
-95.7%
Q2 24
4.8%
-89.5%
Q1 24
5.1%
-156.8%
EPS (diluted)
DV
DV
RARE
RARE
Q4 25
$0.18
$-1.28
Q3 25
$0.06
$-1.81
Q2 25
$0.05
$-1.17
Q1 25
$0.01
$-1.57
Q4 24
$0.14
$-1.34
Q3 24
$0.10
$-1.40
Q2 24
$0.04
$-1.52
Q1 24
$0.04
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DV
DV
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$259.0M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.1B
$-80.0M
Total Assets
$1.4B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DV
DV
RARE
RARE
Q4 25
$259.0M
$421.0M
Q3 25
$200.7M
$202.5M
Q2 25
$216.8M
$176.3M
Q1 25
$174.3M
$127.1M
Q4 24
$310.6M
$174.0M
Q3 24
$362.6M
$150.6M
Q2 24
$338.8M
$480.7M
Q1 24
$334.3M
$112.3M
Stockholders' Equity
DV
DV
RARE
RARE
Q4 25
$1.1B
$-80.0M
Q3 25
$1.1B
$9.2M
Q2 25
$1.1B
$151.3M
Q1 25
$1.0B
$144.2M
Q4 24
$1.1B
$255.0M
Q3 24
$1.1B
$346.8M
Q2 24
$1.1B
$432.4M
Q1 24
$1.1B
$140.3M
Total Assets
DV
DV
RARE
RARE
Q4 25
$1.4B
$1.5B
Q3 25
$1.3B
$1.2B
Q2 25
$1.3B
$1.3B
Q1 25
$1.2B
$1.3B
Q4 24
$1.3B
$1.5B
Q3 24
$1.3B
$1.5B
Q2 24
$1.3B
$1.6B
Q1 24
$1.3B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DV
DV
RARE
RARE
Operating Cash FlowLast quarter
$72.7M
$-99.8M
Free Cash FlowOCF − Capex
$62.1M
$-100.8M
FCF MarginFCF / Revenue
30.2%
-48.6%
Capex IntensityCapex / Revenue
5.1%
0.5%
Cash ConversionOCF / Net Profit
2.48×
TTM Free Cash FlowTrailing 4 quarters
$172.7M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DV
DV
RARE
RARE
Q4 25
$72.7M
$-99.8M
Q3 25
$51.2M
$-91.4M
Q2 25
$49.6M
$-108.3M
Q1 25
$37.7M
$-166.5M
Q4 24
$37.4M
$-79.3M
Q3 24
$54.6M
$-67.0M
Q2 24
$35.9M
$-77.0M
Q1 24
$31.8M
$-190.7M
Free Cash Flow
DV
DV
RARE
RARE
Q4 25
$62.1M
$-100.8M
Q3 25
$39.0M
$-92.7M
Q2 25
$40.1M
$-110.7M
Q1 25
$31.4M
$-167.8M
Q4 24
$30.0M
$-79.5M
Q3 24
$48.4M
$-68.6M
Q2 24
$28.7M
$-79.0M
Q1 24
$25.4M
$-193.9M
FCF Margin
DV
DV
RARE
RARE
Q4 25
30.2%
-48.6%
Q3 25
20.7%
-58.0%
Q2 25
21.2%
-66.5%
Q1 25
19.0%
-120.5%
Q4 24
15.8%
-48.3%
Q3 24
28.5%
-49.2%
Q2 24
18.4%
-53.7%
Q1 24
18.0%
-178.2%
Capex Intensity
DV
DV
RARE
RARE
Q4 25
5.1%
0.5%
Q3 25
6.4%
0.8%
Q2 25
5.0%
1.5%
Q1 25
3.8%
1.0%
Q4 24
3.9%
0.1%
Q3 24
3.7%
1.2%
Q2 24
4.6%
1.4%
Q1 24
4.5%
3.0%
Cash Conversion
DV
DV
RARE
RARE
Q4 25
2.48×
Q3 25
5.02×
Q2 25
5.66×
Q1 25
15.95×
Q4 24
1.60×
Q3 24
3.00×
Q2 24
4.80×
Q1 24
4.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DV
DV

Activation$116.5M57%
Measurement$69.6M34%
Supply Side$19.5M9%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons